Pyxis Oncology Inc (PYXS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pyxis Oncology Inc (PYXS) has a cash flow conversion efficiency ratio of -0.193x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.28 Million) by net assets ($68.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Pyxis Oncology Inc worth for the company's overall valuation and market capitalisation.
Pyxis Oncology Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Pyxis Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pyxis Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pyxis Oncology Inc ranked by their cash flow conversion efficiency. See PYXS cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kudelski
SW:KUD
|
-0.143x |
|
IMI PLC
LSE:IMI
|
0.259x |
|
Norse Atlantic ASA
OL:NORSE
|
-0.059x |
|
Q.BEYOND AG NA O.N. KONV.
XETRA:QBY0
|
0.002x |
|
Valuence Merger Corp I
NASDAQ:VMCA
|
-0.014x |
|
Say Yenilenebilir Enerji Ekipmanları Sanayi ve Ticaret Anonim Şirketi
IS:SAYAS
|
0.025x |
|
JLK Inc
KQ:322510
|
-0.056x |
|
Wilton Makmur Indonesia Tbk
JK:SQMI
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Pyxis Oncology Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Pyxis Oncology Inc from 2019 to 2024. View latest Pyxis Oncology Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $120.75 Million | $-57.67 Million | -0.478x | +15.09% |
| 2023-12-31 | $125.70 Million | $-70.71 Million | -0.563x | -1.26% |
| 2022-12-31 | $160.82 Million | $-89.33 Million | -0.555x | -310.90% |
| 2021-12-31 | $261.31 Million | $-35.33 Million | -0.135x | -120.97% |
| 2020-12-31 | $-15.64 Million | $-10.08 Million | 0.645x | -17.26% |
| 2019-12-31 | $-2.87 Million | $-2.24 Million | 0.779x | -- |
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candida… Read more